The COVID-19 pandemic has impacted drug development, and rare disease drug development in particular – and the industry in general grapples with challenges in this new clinical trial environment.
In this episode for our Coronavirus Special Edition Series, Zizi Imatorbhebhe, Global Lead of Rare Disease Clinical Development at Syneos Health, discusses the numerous challenges involved in rare disease drug development and how the pandemic has heightened the need to adapt innovations and strategic considerations to accelerate development.
To read more about rare disease clinical trials in the age of COVID-19, download our white paper.
Stay tuned for more installments of the Coronavirus Special Edition Series, which explores, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].
* This episode was recorded on 5/6/2020.